Skip to main content

Advertisement

SpringerLink
Log in

Weight loss in neurodegenerative disorders

  • ORIGINAL COMMUNICATION
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

Unintended weight loss frequently complicates the course of many neurodegenerative disorders and can contribute substantially to both morbidity and mortality. This will be illustrated here by reviewing the characteristics of unintended weight loss in the three major neurodegenerative disorders: Alzheimer’s disease, Parkinson’s disease and Huntington’s disease. A common denominator of weight loss in these neurodegenerative disorders is its typically complex pathophysiology. Timely recognition of the underlying pathophysiological process is of crucial importance, since a tailored treatment of weight loss can considerably improve the quality of life. This treatment is, primarily, comprised of a number of methods of increasing energy intake. Moreover, there are indications for defects in the systemic energy homeostasis and gastrointestinal function, which may also serve as therapeutic targets. However, the clinical merits of such interventions have yet to be demonstrated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Evans DA, Smith LA, Scherr PA, Albert MS, Funkenstein HH, Hebert LE (1991) Risk of death from Alzheimer’s disease in a community population of older persons. Am J Epidemiol 134(4):403–412

    PubMed  CAS  Google Scholar 

  2. Guyonnet S, Nourhashemi F, Ousset PJ, Micas M, Ghisolfi A, Vellas B, et al. (1998) Factors associated with weight loss in Alzheimer’s disease. J Nutr Health Aging 2(2):107–109

    PubMed  CAS  Google Scholar 

  3. Craft S (2005) Insulin resistance syndrome and Alzheimer’s disease: age- and obesity-related effects on memory, amyloid, and inflammation. Neurobiol Aging 26(Suppl 1):65–69

    Article  PubMed  CAS  Google Scholar 

  4. Craft S, Watson GS (2004) Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 3(3):169–178

    Article  PubMed  CAS  Google Scholar 

  5. Gillette GS, Abellan VK, Alix E, Andrieu S, Belmin J, Berrut G, et al. (2007) IANA (International Academy on Nutrition and Aging) Expert Group: weight loss and Alzheimer’s disease. J Nutr Health Aging 11(1):38–48

    Google Scholar 

  6. Tamura BK, Masaki KH, Blanchette P (2007) Weight loss in patients with Alzheimer’s disease. J Nutr Elder 26 (3–4):21–38

    Article  PubMed  Google Scholar 

  7. Gillette-Guyonnet S, Nourhashemi F, Andrieu S, de G, I, Ousset PJ, Riviere D, et al. (2000) Weight loss in Alzheimer disease. Am J Clin Nutr 71(2): 637S–642S

    PubMed  CAS  Google Scholar 

  8. Buchman AS, Wilson RS, Bienias JL, Shah RC, Evans DA, Bennett DA (2005) Change in body mass index and risk of incident Alzheimer disease. Neurology 65(6):892–897

    Article  PubMed  CAS  Google Scholar 

  9. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34(7):939–944

    PubMed  CAS  Google Scholar 

  10. Whitmer RA, Gunderson EP, Barrett- Connor E, Quesenberry CP Jr, Yaffe K (2005) Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ 330(7504):1360

    Article  PubMed  Google Scholar 

  11. Luchsinger JA, Patel B, Tang MX, Schupf N, Mayeux R (2007) Measures of adiposity and dementia risk in elderly persons. Arch Neurol 64(3):392–398

    Article  PubMed  Google Scholar 

  12. Nutt JG, Wooten GF (2005) Clinical practice. Diagnosis and initial management of Parkinson’s disease. N Engl J Med 353(10):1021–1027

    Article  PubMed  CAS  Google Scholar 

  13. Chaudhuri KR, Healy DG, Schapira AH (2006) Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol 5(3):235–245

    Article  PubMed  Google Scholar 

  14. Bachmann CG, Trenkwalder C (2006) Body weight in patients with Parkinson’s disease. Mov Disord 21(11):1824–1830

    Article  PubMed  Google Scholar 

  15. Chen H, Zhang SM, Hernan MA, Willett WC, Ascherio A (2003) Weight loss in Parkinson’s disease. Ann Neurol 53(5):676–679

    Article  PubMed  Google Scholar 

  16. Abbott RD, Ross GW, White LR, Nelson JS, Masaki KH, Tanner CM, et al. (2002) Midlife adiposity and the future risk of Parkinson’s disease. Neurology 59(7):1051–1057

    PubMed  CAS  Google Scholar 

  17. Bates G, Harper PS, Jones L (2002) Huntington’s Disease. Third edition. Oxford University Press

  18. Kremer HP, Roos RA (1992) Weight loss in Huntington’s disease. Arch Neurol 49(4):349

    PubMed  CAS  Google Scholar 

  19. Morales LM, Estevez J, Suarez H, Villalobos R, Chacin DB, Bonilla E (1989) Nutritional evaluation of Huntington disease patients. Am J Clin Nutr 50(1):145–150

    PubMed  CAS  Google Scholar 

  20. Djousse L, Knowlton B, Cupples LA, Marder K, Shoulson I, Myers RH (2002) Weight loss in early stage of Huntington’s disease. Neurology 59(9):1325–1330

    PubMed  CAS  Google Scholar 

  21. Trejo A, Boll MC, Alonso ME, Ochoa A, Velasquez L (2005) Use of oral nutritional supplements in patients with Huntington’s disease. Nutrition 21(9):889–894

    PubMed  CAS  Google Scholar 

  22. Kremer HP (1992) The lateral hypothalamus in Huntington’s, Alzheimer’s and Parkinson’s disease. Leiden, The Netherlands (Thesis)

  23. Farrer LA, Meaney FJ (1985) An anthropometric assessment of Huntington’s disease patients and families. Am J Phys Anthropol 67(3):185–194

    Article  PubMed  CAS  Google Scholar 

  24. Farrer LA, Yu PL (1985) Anthropometric discrimination among affected, at-risk, and not-at-risk individuals in families with Huntington disease. Am J Med Genet 21(2):307–316

    Article  PubMed  CAS  Google Scholar 

  25. Trejo A, Tarrats RM, Alonso ME, Boll MC, Ochoa A, Velasquez L (2004) Assessment of the nutrition status of patients with Huntington’s disease. Nutrition 20(2):192–196

    Article  PubMed  CAS  Google Scholar 

  26. Pratley RE, Salbe AD, Ravussin E, Caviness JN (2000) Higher sedentary energy expenditure in patients with Huntington’s disease. Ann Neurol 47(1):64–70

    Article  PubMed  CAS  Google Scholar 

  27. Lanska DJ, Lanska MJ, Lavine L, Schoenberg BS (1988) Conditions associated with Huntington’s disease at death. A case-control study. Arch Neurol 45(8):878–880

    PubMed  CAS  Google Scholar 

  28. Myers RH, Sax DS, Koroshetz WJ, Mastromauro C, Cupples LA, Kiely DK, et al. (1991) Factors associated with slow progression in Huntington’s disease. Arch Neurol 48(8):800–804

    PubMed  CAS  Google Scholar 

  29. National Collaborating Centre for Acute Care (2006) Nutrition support in adults: Oral nutrition support, enteral tube feeding and parenteral nutrition. Report. London

  30. Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW (2006) Central nervous system control of food intake and body weight. Nature 443(7109):289–295

    Article  PubMed  CAS  Google Scholar 

  31. Sandoval D, Cota D, Seeley RJ (2008) The integrative role of CNS fuel-sensing mechanisms in energy balance and glucose regulation. Annu Rev Physiol 70:513–535

    Article  PubMed  CAS  Google Scholar 

  32. White HK (2005) Nutrition in advanced Alzheimer’s disease. N C Med J 66(4):307–312

    PubMed  Google Scholar 

  33. Van Raamsdonk JM, Gibson WT, Pearson J, Murphy Z, Lu G, Leavitt BR, et al. (2006) Body weight is modulated by levels of full-length Huntingtin. Hum Mol Genet 15(9):1513–1523

    Article  PubMed  CAS  Google Scholar 

  34. Hickson M (2006) Malnutrition and ageing. Postgrad Med J 82(963):2–8

    Article  PubMed  CAS  Google Scholar 

  35. Thomas DR, Ashmen W, Morley JE, Evans WJ (2000) Nutritional management in long-term care: development of a clinical guideline. Council for Nutritional Strategies in Long-Term Care. J Gerontol A Biol Sci Med Sci 55(12):M725–M734

    PubMed  CAS  Google Scholar 

  36. Malnutrition Universal Screening Tool. http://www.bapen.org.uk/must_tool. html

  37. Mini Nutritional Assessment. http:// www.nestle-nutrition.com/tools/mna. aspx

  38. Stratton RJ, King CL, Stroud MA, Jackson AA, Elia M (2006) ‘Malnutrition Universal Screening Tool’ predicts mortality and length of hospital stay in acutely ill elderly. Br J Nutr 95(2):325–330

    Article  PubMed  CAS  Google Scholar 

  39. Guigoz Y (2006) The Mini Nutritional Assessment (MNA) review of the literature – What does it tell us? J Nutr Health Aging 10(6):466–485

    PubMed  CAS  Google Scholar 

  40. Volkert D, Berner YN, Berry E, Cederholm T, Coti BP, Milne A, et al. (2006) ESPEN Guidelines on Enteral Nutrition: Geriatrics. Clin Nutr 25(2): 330–360

    Article  PubMed  CAS  Google Scholar 

  41. Finley B (1997) Nutritional needs of the person with Alzheimer’s disease: practical approaches to quality care. J Am Diet Assoc 97(10 Suppl 2):S177–S180

    Article  PubMed  CAS  Google Scholar 

  42. Ragneskog H, Brane G, Karlsson I, Kihlgren M (1996) Influence of dinner music on food intake and symptoms common in dementia. Scand J Caring Sci 10(1):11–17

    PubMed  CAS  Google Scholar 

  43. Nijs KA, de Graaf C, Kok FJ, van Staveren WA (2006) Effect of family style mealtimes on quality of life, physical performance, and body weight of nursing home residents: cluster randomised controlled trial. BMJ 332(7551):1180–1184

    Article  PubMed  Google Scholar 

  44. Poehlman ET, Dvorak RV (2000) Energy expenditure, energy intake, and weight loss in Alzheimer disease. Am J Clin Nutr 71(2):650S–655S

    PubMed  CAS  Google Scholar 

  45. Kishi T, Elmquist JK (2005) Body weight is regulated by the brain: a link between feeding and emotion. Mol Psychiatry 10(2):132–146

    Article  PubMed  CAS  Google Scholar 

  46. Rigler SK, Webb MJ, Redford L, Brown EF, Zhou J, Wallace D (2001) Weight outcomes among antidepressant users in nursing facilities. J Am Geriatr Soc 49(1):49–55

    Article  PubMed  CAS  Google Scholar 

  47. Masand PS, Gupta S (2002) Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine. Ann Clin Psychiatry 14(3):175–182

    PubMed  Google Scholar 

  48. Deberdt WG, Dysken MW, Rappaport SA, Feldman PD, Young CA, Hay DP, et al. (2005) Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia. Am J Geriatr Psychiatry 13(8):722–730

    PubMed  Google Scholar 

  49. Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, et al. (2006) Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med 355(15):1525–1538

    Article  PubMed  CAS  Google Scholar 

  50. White HK, McConnell ES, Bales CW, Kuchibhatla M (2004) A 6-month observational study of the relationship between weight loss and behavioral symptoms in institutionalized Alzheimer’s disease subjects. J Am Med Dir Assoc 5(2):89–97

    Article  PubMed  Google Scholar 

  51. Levi S, Cox M, Lugon M, Hodkinson M, Tomkins A (1990) Increased energy expenditure in Parkinson’s disease. BMJ 301(6763):1256–1257

    Article  PubMed  CAS  Google Scholar 

  52. Markus HS, Cox M, Tomkins AM (1992) Raised resting energy expenditure in Parkinson’s disease and its relationship to muscle rigidity. Clin Sci (Lond) 83(2):199–204

    PubMed  CAS  Google Scholar 

  53. Montaurier C, Morio B, Bannier S, Derost P, Arnaud P, Brandolini-Bunlon M, et al. (2007) Mechanisms of body weight gain in patients with Parkinson’s disease after subthalamic stimulation. Brain 130(Pt 7):1808–1818

    Article  PubMed  CAS  Google Scholar 

  54. Gaba AM, Zhang K, Marder K, Moskowitz CB, Werner P, Boozer CN (2005) Energy balance in early-stage Huntington disease. Am J Clin Nutr 81(6):1335–1341

    PubMed  CAS  Google Scholar 

  55. Toth MJ, Fishman PS, Poehlman ET (1997) Free-living daily energy expenditure in patients with Parkinson’s disease. Neurology 48(1):88–91

    PubMed  CAS  Google Scholar 

  56. Mochel F, Charles P, Seguin F, Barritault J, Coussieu C, Perin L, et al. (2007) Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression. PLoS ONE 2(7):e647

    Article  PubMed  CAS  Google Scholar 

  57. Chouinard J (2000) Dysphagia in Alzheimer disease: a review. J Nutr Health Aging 4(4):214–217

    PubMed  CAS  Google Scholar 

  58. Pfeiffer RF (2003) Gastrointestinal dysfunction in Parkinson’s disease. Lancet Neurol 2(2):107–116

    Article  PubMed  Google Scholar 

  59. Kagel MC, Leopold NA (1992) Dysphagia in Huntington’s disease: a 16-year retrospective. Dysphagia 7(2):106–114

    Article  PubMed  CAS  Google Scholar 

  60. Hawkes C (2006) Olfaction in neurodegenerative disorder. Adv Otorhinolaryngol 63:133–151

    PubMed  Google Scholar 

  61. Mathey MF, Siebelink E, de Graaf C, van Staveren WA (2001) Flavor enhancement of food improves dietary intake and nutritional status of elderly nursing home residents. J Gerontol A Biol Sci Med Sci 56(4):M200–M205

    PubMed  CAS  Google Scholar 

  62. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT (1998) A 24- week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Donepezil Study Group. Neurology 50(1):136–145

    PubMed  CAS  Google Scholar 

  63. Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal Bianco P, et al. (1999) Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. BMJ 318(7184):633–638

    PubMed  CAS  Google Scholar 

  64. Raskind MA, Peskind ER, Wessel T, Yuan W (2000) Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 54(12):2261–2268

    PubMed  CAS  Google Scholar 

  65. Vardi J, Oberman Z, Rabey I, Streifler M, Ayalon D, Herzberg M (1976) Weight loss in patients treated longterm with levodopa. Metabolic aspects. J Neurol Sci 30(1):33–40

    Article  PubMed  CAS  Google Scholar 

  66. Beyer PL, Palarino MY, Michalek D, Busenbark K, Koller WC (1995) Weight change and body composition in patients with Parkinson’s disease. J Am Diet Assoc 95(9):979–983

    Article  PubMed  CAS  Google Scholar 

  67. Palhagen S, Lorefalt B, Carlsson M, Ganowiak W, Toss G, Unosson M, et al. (2005) Does L-dopa treatment contribute to reduction in body weight in elderly patients with Parkinson’s disease? Acta Neurol Scand 111(1):12–20

    Article  PubMed  CAS  Google Scholar 

  68. Kumru H, Santamaria J, Valldeoriola F, Marti MJ, Tolosa E (2006) Increase in body weight after pramipexole treatment in Parkinson’s disease. Mov Disord 21(11):1972–1974

    Article  PubMed  Google Scholar 

  69. Huntington Study Group (2006) Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 66(3):366–372

    Google Scholar 

  70. Tabrizi SJ, Blamire AM, Manners DN, Rajagopalan B, Styles P, Schapira AH, et al. (2005) High-dose creatine therapy for Huntington disease: a 2-year clinical and MRS study. Neurology 64(9):1655–1656

    Article  PubMed  CAS  Google Scholar 

  71. Arabia G, Zappia M, Bosco D, Crescibene L, Bagala A, Bastone L, et al. (2002) Body weight, levodopa pharmacokinetics and dyskinesia in Parkinson’s disease. Neurol Sci 23(Suppl 2):S53–S54

    Article  PubMed  Google Scholar 

  72. Gil GP, Ramirez Diaz SP, Ribera Casado JM (2003) Dementia and Nutrition. Intervention study in institutionalized patients with Alzheimer disease. J Nutr Health Aging 7(5):304–308

    Google Scholar 

  73. Lauque S, Arnaud-Battandier F, Gillette S, Plaze JM, Andrieu S, Cantet C, et al. (2004) Improvement of weight and fat-free mass with oral nutritional supplementation in patients with Alzheimer’s disease at risk of malnutrition: a prospective randomized study. J Am Geriatr Soc 52(10):1702–1707

    Article  PubMed  Google Scholar 

  74. Salas-Salvado J, Torres M, Planas M, Altimir S, Pagan C, Gonzalez ME, et al. (2005) Effect of oral administration of a whole formula diet on nutritional and cognitive status in patients with Alzheimer’s disease. Clin Nutr 24(3):390–397

    Article  PubMed  CAS  Google Scholar 

  75. World Health Organisation (2004) Human energy requirements: Report of a joint FAO/WHO/UNU expert consultation. FAO FOOD AND NUTRITION TECHNICAL REPORT SERIES 1. Report. Rome

  76. Gaillard C, Alix E, Salle A, Berrut G, Ritz P (2007) Energy requirements in frail elderly people: a review of the literature. Clin Nutr 26(1):16–24

    Article  PubMed  CAS  Google Scholar 

  77. de Groot CP, van den BT, van Staveren W (1999) Energy intake and micronutrient intake in elderly Europeans: seeking the minimum requirement in the SENECA study. Age Ageing 28(5):469–474

    Article  PubMed  Google Scholar 

  78. Aziz NA, Swaab DF, Pijl H, Roos RA (2007) Hypothalamic dysfunction and neuroendocrine and metabolic alterations in Huntington’s disease: clinical consequences and therapeutic implications. Rev Neurosci 18(3–4):223–251

    PubMed  CAS  Google Scholar 

  79. Swaab DF (2004) The human hypothalamus: basic and clinical aspects, part II: neuropathology of the human hypothalamus and adjacent structures. Amsterdam, The Netherlands: Elsevier

  80. Thannickal TC, Lai YY, Siegel JM (2007) Hypocretin (orexin) cell loss in Parkinson’s disease. Brain 130(Pt 6):1586–1595

    Article  PubMed  Google Scholar 

  81. Fronczek R, Overeem S, Lee SY, Hegeman IM, van Pelt J, Van Duinen SG, et al. (2007) Hypocretin (orexin) loss in Parkinson’s disease. Brain 130(Pt 6):1577–1585

    Article  PubMed  Google Scholar 

  82. Kunig G, Leenders KL, Martin-Solch C, Missimer J, Magyar S, Schultz W (2000) Reduced reward processing in the brains of Parkinsonian patients. Neuroreport 11(17):3681–3687

    Article  PubMed  CAS  Google Scholar 

  83. Grundman M, Corey-Bloom J, Jernigan T, Archibald S, Thal LJ (1996) Low body weight in Alzheimer’s disease is associated with mesial temporal cortex atrophy. Neurology 46(6):1585–1591

    PubMed  CAS  Google Scholar 

  84. Aziz A, Fronczek R, Maat-Schieman M, Unmehopa U, Roelandse F, Overeem S, et al. (2008) Hypocretin and melaninconcentrating hormone in patients with Huntington disease. Brain Pathol 18(4):474–483

    PubMed  CAS  Google Scholar 

  85. Rypkema G, Adang E, Dicke H, Naber T, de Swart B, Disselhorst L, et al. (2004) Cost-effectiveness of an interdisciplinary intervention in geriatric inpatients to prevent malnutrition. J Nutr Health Aging 8(2):122–127

    PubMed  CAS  Google Scholar 

  86. Hamilton JM, Wolfson T, Peavy GM, Jacobson MW, Corey-Bloom J (2004) Rate and correlates of weight change in Huntington’s disease. J Neurol Neurosurg Psychiatry 75(2):209–212

    Article  PubMed  CAS  Google Scholar 

  87. Gonzalez De Aguilar JL, Rene F, Dupuis L, Loeffler JP (2003) Neuroendocrinology of neurodegenerative diseases. Insights from transgenic mouse models. Neuroendocrinology 78(5):244–252

    Article  CAS  Google Scholar 

  88. Dalrymple A, Wild EJ, Joubert R, Sathasivam K, Bjorkqvist M, Petersen A, et al. (2007) Proteomic profiling of plasma in Huntington’s disease reveals neuroinflammatory activation and biomarker candidates. J Proteome Res 6(7):2833–2840

    Article  PubMed  CAS  Google Scholar 

  89. Dobbs RJ, Dobbs SM, Weller C, Bjarnason IT, Oxlade NL, Charlett A, et al. (2005) Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Part 1: eradication of Helicobacter in the cachexia of idiopathic parkinsonism. Helicobacter 10(4):267–275

    Article  PubMed  CAS  Google Scholar 

  90. Mahieux F, Couderc R, Fenelon G, Maachi M (2006) Relationships between weight loss and circulating cytokines in patients with Alzheimer’s disease. Psychol Neuropsychiatr Vieil 4(4):281–286

    PubMed  Google Scholar 

  91. Hartmann A, Veldhuis JD, Deuschle M, Standhardt H, Heuser I, Stypula G, et al. (1997) Twenty-four hour cortisol release profiles in patients with Alzheimer’s and Parkinson’s disease compared to normal controls: ultradian secretory pulsatility and diurnal variation. Neurobiol Aging 18(3):285–289

    Article  PubMed  CAS  Google Scholar 

  92. Okun MS, DeLong MR, Hanfelt J, Gearing M, Levey A (2004) Plasma testosterone levels in Alzheimer and Parkinson diseases. Neurology 62(3):411–413

    PubMed  CAS  Google Scholar 

  93. Markianos M, Panas M, Kalfakis N, Vassilopoulos D (2005) Plasma testosterone in male patients with Huntington’s disease: relations to severity of illness and dementia. Ann Neurol 57(4):520–525

    Article  PubMed  CAS  Google Scholar 

  94. Fain JN, Del Mar NA, Meade CA, Reiner A, Goldowitz D (2001) Abnormalities in the functioning of adipocytes from R6/2 mice that are transgenic for the Huntington’s disease mutation. Hum Mol Genet 10(2):145–152

    Article  PubMed  CAS  Google Scholar 

  95. Lodi R, Schapira AH, Manners D, Styles P, Wood NW, Taylor DJ, et al. (2000) Abnormal in vivo skeletal muscle energy metabolism in Huntington’s disease and dentatorubropallidoluysian atrophy. Ann Neurol 48(1):72–76

    Article  PubMed  CAS  Google Scholar 

  96. Saft C, Zange J, Andrich J, Muller K, Lindenberg K, Landwehrmeyer B, et al. (2005) Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington’s disease. Mov Disord 20(6):674–679

    Article  PubMed  Google Scholar 

  97. Vanhanen M, Kivipelto M, Koivisto K, Kuusisto J, Mykkanen L, Helkala EL, et al. (2001) APOE-epsilon4 is associated with weight loss in women with AD: a population-based study. Neurology 56(5):655–659

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Leiden University Medical Centre, Dept. of Neurology, K-05-Q 110, 9600, Albinusdreef 2, 2300 RC, Leiden, The Netherlands

    N. A. Aziz MSc & R. A. C. Roos MD

  2. Dept. of Endocrinology and Metabolic, Diseases, Leiden University Medical Centre, Leiden, The Netherlands

    H. Pijl MD

  3. Dept. of Neurology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

    M. A. van der Marck MSc & B. R. Bloem MD

  4. Dept. of Geriatric Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

    M. G. M. Olde Rikkert MD

Authors
  1. N. A. Aziz MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. A. van der Marck MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Pijl MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. G. M. Olde Rikkert MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B. R. Bloem MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R. A. C. Roos MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N. A. Aziz MSc.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Aziz, N.A., van der Marck, M.A., Pijl, H. et al. Weight loss in neurodegenerative disorders. J Neurol 255, 1872–1880 (2008). https://doi.org/10.1007/s00415-009-0062-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-009-0062-8

Key words

Search

Navigation